June 25, 2019 | City of Hope
City of Hope has accelerated its plans for a $1 billion comprehensive cancer campus in Orange County, bringing highly specialized cancer care, clinical trials, precision medicine and early detection to the nation’s sixth most populous county.
City of Hope to participate in NCI-MATCH clinical trial
April 5, 2019 | City of Hope
City of Hope’s Clinical Molecular Diagnostic Laboratory (CMDL) is participating as a CLIA-Certified/Accredited laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial.
New Study: Deploying Genetic Screens Early May Offer Some Benefits
February 7, 2017 | Jyoti Madhusoodanan
Next-generation sequencing (NGS) tests can quickly pinpoint tumor mutations that can be targeted with specific drugs, offering a route to precision therapies for many cancer types. Coupled with new drugs that target tumor-specific genomic changes, NGS tests carry the potential to transform modern cancer care.
NCI-MATCH Trial focuses on mutations for rare cancers, not tumor site
April 15, 2015 | Nicole Levine
Precision medicine is becoming a reality for cancers with genetic mutations that are practically household names, such as those behind some breast cancers and lung cancers. A new multicenter trial focuses on providing precision treatments for rare cancers based on genetics, not tumor site.